Chinese regulators have approved Akeso’s cancer therapy, ivonescimab, for patients with non-small cell lung cancer who test positive for PD-L1 protein. The treatment reduced the risk of tumor progression by 49% compared to Merck’s Keytruda and showed a 22% lower mortality rate in an interim analysis involving 157 patient deaths.
Source: https://www.statnews.com/2025/04/25/akeso-wins-chinese-approval-for-cancer-drug-ivonescimab-keytruda-rival